Publications
5674 Results
- Journal / Conference
- San Antoino Breast Cancer Symposium, abst. #p3-10-26; poster
- Year
- 2010
- Research Committee(s)
- Breast
- Study Number(s)
- JMA17
Quantitative protein and gene expression biomarkers of tamoxifen and letrozole recurrence in the NCIC CTG MA.17 cohort
- Journal / Conference
- San Antonio Breast Cancer Symposium, #S1-1; poster
- Year
- 2010
- Research Committee(s)
- Breast
Final analysis of NCIC CTG MA.27: a randomized phase III trial of exemestane versus anastrozole in post-menopausal women with hormone receptor positive primary breast cancer
- Journal / Conference
- Journal of Clinical Oncology 28:15s, 2010 (suppl; abstr 7013); ASCO annual meeting; poster
- Year
- 2010
- Research Committee(s)
- Lung
- Study Number(s)
- S0424
KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424
- Journal / Conference
- Journal of Clinical Oncology 28:18s, 2010 (suppl; abstr LBA7005); ASCO annual meeting; poster
- Year
- 2010
- Research Committee(s)
- Lung
A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19
- Journal / Conference
- Journal of Clinical Oncology 28:18s, 2010 (suppl; abstr CRA7004); ASCO Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Lung
- Study Number(s)
- E5597
A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC)
- Journal / Conference
- Cancer Research 2010; 70(24 suppl 2 ): abstr PD05-01; SABCS annual meeting; poster discussion
- Year
- 2010
- Research Committee(s)
- Breast
Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study
- Journal / Conference
- Journal of Clinical Oncology 28:15s:(suppl; abstr TPS129); Trials in Progress poster presentation
- Year
- 2010
- Research Committee(s)
- Breast
N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer
- Journal / Conference
- Int. J. Radiat. Oncol. Biol. Phys. 76(5):1305-1313
- Year
- 2010
- Research Committee(s)
- Breast
- PMID
- PMID19747781
- PMC
- PMC3670136
- Study Number(s)
- SWOG-9114 (INT-0163) (CALGB-9082)
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082
- Journal / Conference
- Journal of Clinical Oncology 28(1):77-82
- Year
- 2010
- Research Committee(s)
- Breast
- PMID
- PMID19901117
- PMC
- PMC2799234